37th ACS National Medicinal Chemistry Symposium

American Chemical Society
Division of Medicinal Chemistry

 New York City, NY, United States    June 26-29, 2022

Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery

Discovery and Development of Macrocyclic Peptides for the Treatment of Complement-Mediated Disorders

Dr Susan ASHWELL
Dr Susan ASHWELL
UCB, Cambridge, United States
Read more

Impact of Structure Based Drug Design in GPCR Lead Optimisation Strategies

Dr Miles CONGREVE
Dr Miles CONGREVE
SOSEI HEPTARES, Welwyn Garden City, United Kingdom
Read more

Targeted Protein Degradation Strategies

Dr Chris DE SAVI
Dr Chris DE SAVI
KYMERA THERAPEUTICS, Watertown, United States
Read more

Translating RNA Sequence into Lead Small Molecule Medicines

Prof. Matthew DISNEY
Prof. Matthew DISNEY
SCRIPPS RESEARCH INSTITUTE, Jupiter, United States
Read more

Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets

Prof. Kyle HADDEN
Prof. Kyle HADDEN
UNIVERSITY OF CONNECTICUT, Storrs, United States
Read more

Integrating DNA-Encoded Library Technologies in Lead Discovery

Dr Lisa MARCAURELLE
Dr Lisa MARCAURELLE
GSK, Cambridge, United States
Read more

Session 2: New Directions in Targeting DNA Damage Repair (DDR)

M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies

Dr Thomas FUCHSS
Dr Thomas FUCHSS
MERCK KGAA, HEALTHCARE, Darmstadt, Germany
Read more

Discovery of human DNA Polymerase theta (Polθ) Inhibitors

Dr Robert HEALD
Dr Robert HEALD
ARTIOS PHARMA LTD, Cambridge, United Kingdom
Read more

Damage Incorporated: Discovery of ATR Inhibitor BAY 1895344 with Favorable PK Properties and Promising Anti-Tumor Efficacy in Monotherapy and Combination in Preclinical Tumor Models

Dr Ulrich LÜCKING
Dr Ulrich LÜCKING
FORX THERAPEUTICS, Basel, Switzerland
Read more

The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response

Prof. Phil REIGAN
Prof. Phil REIGAN
UNIVERSITY OF COLORADO, Aurora, United States
Read more

Session 3: Hot Targets from NYC Academic and Biotech Scene

Designing and Combining Cancer's Off Switches

Dr Karen AKINSANYA
Dr Karen AKINSANYA
SCHRODINGER, New York City, United States
Read more

Rational Design of Inhibitors of Protein-Protein Interactions

Prof. Paramjit ARORA
Prof. Paramjit ARORA
NYU, New York, United States
Read more

Next Generation Drug Discovery

Dr Steve COLLETTI
Dr Steve COLLETTI
ZYMERGEN INC., New York, United States
Read more

Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd)

Dr John GINN
Dr John GINN
TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States
Read more

Therapeutic Potential of the Gut-Brain Axis

Dr Iyassu SEBHAT
Dr Iyassu SEBHAT
KALLYOPE, New Jersey, United States
Read more

Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease

Chasing Challenging Targets: Development of Selective Inhibitors of the Autophagy Pathway to Impact Cancer Therapy

Prof. Leslie ALDRICH
Prof. Leslie ALDRICH
UNIVERISTY OF ILLINOIS AT CHICAGO, Chicago, United States
Read more

Title of talk to be confirmed

Dr Peter FULLER
Dr Peter FULLER
MERCK & CO. INC., Boston, United States

Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration

Prof. Evripidis GAVATHIOTIS
Prof. Evripidis GAVATHIOTIS
ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States
Read more

Activating PTEN-Induced Kinase 1 (PINK1) for Parkinson’s Disease

Dr Nicholas HERTZ
Dr Nicholas HERTZ
MITOKININ INC, San Francisco, United States
Read more

Unraveling Autophagy in Cancer Using Chemical Genetics

Prof. Jeff MACKEIGAN
Prof. Jeff MACKEIGAN
MICHIGAN STATE UNIVERSITY, East Lansing, United States
Read more

Session 5: Next Generation Therapies Shaped by Clinical Data

Discovery of LPA1 antagonists for the treatment of Pulmonary Fibrotic Diseases

Dr Peter CHENG
Dr Peter CHENG
BRISTOL-MYERS SQUIBB R & D, Hopewell, United States
Read more

Title of talk to be announced

Dr David GRIFFITH
Dr David GRIFFITH
PFIZER INC., Cambridge, United States
Read more

Discovery of Risdiplam, a Medicine for the Treatment of Spinal Muscular Atrophy

Dr Hasane RATNI
Dr Hasane RATNI
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland
Read more

Evolution of Clinical PI3K Inhibitors at Genentech

Dr Steve STABEN
Dr Steve STABEN
GENENTECH, South San Francisco, United States
Read more

The Invention of MK-8262, a CETP Inhibitor for the Treatment of Coronary Heart Disease

Dr Petr VACHAL
Dr Petr VACHAL
MERCK & CO. INC (MSD), Kenilworth, United States
Read more

Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

Discovery of Nix-TB as a Novel Regimen that Significantly Shortens Treatment of Tuberculosis

Dr Christopher B. COOPER
Dr Christopher B. COOPER
TB ALLIANCE, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, New York, United States
Read more

Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor

Dr Kristine E. FRANK
Dr Kristine E. FRANK
ABBVIE, North Chicago, United States
Read more

Anticancer Drug Discovery from Pets to People, the Story of PAC-1

Prof. Paul J.  HERGENROTHER
Prof. Paul J. HERGENROTHER
UNIVERSITY OF ILLINOIS, Urbana, United States
Read more

From Concept to Clinic: the Story of M1 and mGlu4 Positive Allosteric Modulators (PAMs)

Prof. Craig LINDSLEY
Prof. Craig LINDSLEY
VANDERBILT UNIVERSITY, Nashville, United States
Read more

Discovery of Fenebrutinib (rBTK) for the Treatment of Autoimmune Disorders

Dr Wendy YOUNG
Dr Wendy YOUNG
MPM CAPITAL POWERING BREAKTHROUGHS IN LIFE SCIENCES, Brisbane, United States
Read more

Award Session

2022 Division of Medicinal Chemistry Award Lecture

2022 IUPAC-Richter Prize Lecture